Public market insider selling at HLS Therapeutics (HLS)

Public market insider selling at HLS Therapeutics (T:HLS)

Gregory David Gubitz, a Director, disposed of 147,500 Common Shares on a direct ownership basis at a price of $17.000 on November 19th, 2020. The insider also disposed of 52,500 Common Shares on an indirect ownership basis for registered holder Grosvenor Ventures Inc. at a price of $17.000 on November 19th, 2020. This represents a $3,400,000 divestment of the company's shares and an account share holdings change of -100.0%.

HLS Therapeutics is in the Drug Retailers Sub Industry Group under the Consumer Non-Cyclicals Sector.

HLS Therapeutics Inc is a Canada-based company specialized in the pharmaceutical industry. The Company acquires and distributes commercial stage and branded pharmaceutical drugs for the North American markets. The Company focuses mainly on treatment products for the central nervous system and cardiovascular specialties in Canada. Its product pipeline includes clozaril, for the treatment of schizophrenia disorders; absorica, for treatment of skin disease, such as acne; vascepa, for the treatment of hypertriglyceridemia, and trinomial for cardiovascular risk reduction. Apart from its operation in a number of regions in Canada, such as Toronto, Ontario, and Montreal, the Company also operates in the United States.